Citius Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing first-in-class critical care and oncology products. In December 2025, it became a commercial-stage company through the launch of LYMPHIR by its majority-owned subsidiary Citius Oncology, while still advancing late-stage assets such as Mino-Lok, Halo-Lido, and NoveCite.
0.62
0.13
| % | |
|---|---|
| Commercial oncology product | 70% LYMPHIR is the company's commercial immunotherapy for persistent or recurrent CTCL. |
| Late-stage critical care anti-infective | 15% Mino-Lok is an antibiotic lock solution intended to salvage infected catheters. |
| Topical prescription product | 5% Halo-Lido is a corticosteroid-lidocaine formulation for hemorrhoid symptom relief. |
| Cell therapy development asset | 5% NoveCite is a mesenchymal stem cell program for acute respiratory distress syndrome. |
| Business development and commercialization | 5% This includes in-licensing, development, and third-party commercialization support. |
The company sells into narrow specialty physician and hospital channels, especially in oncology and critical care...
Buy or prescribe LYMPHIR for CTCL patients because it addresses a rare oncology indication with limited options.
Would use Mino-Lok in catheter infection settings to salvage lines and avoid catheter replacement.
Influence access and reimbursement for specialty products by evaluating clinical value and cost-effectiveness.
Cardinal Health, Cencora, McKesson, and EVERSANA support product distribution and launch execution.
End users for Halo-Lido and NoveCite, though these programs remain development-stage or pre-commercial.
Citius Pharmaceuticals is headquartered in Cranford, New Jersey and operates primarily from the United States...
The company is focused on building value through a small number of specialty products that can be commercialized with a...
It is the first approved and launched product and the main near-term revenue driver.
The company has limited cash and needs to preserve resources while advancing multiple programs.
Mino-Lok, Halo-Lido, and NoveCite provide future optionality beyond LYMPHIR.
Management is seeking ways to maximize shareholder value and fund future operations.
Citius remains highly dependent on successful commercialization of LYMPHIR and on external financing, with a history of...
The company has a history of losses, negative working capital, and limited cash, so it must raise external capital or generate product revenue.
Revenue depends on successful launch, payer access, and physician adoption in a narrow oncology market.
The company depends on a limited number of cGMP-compliant facilities for commercial supply.
Drug development and commercialization require FDA and other regulatory approvals and ongoing compliance.
Sales, marketing, and distribution are outsourced, so execution depends on third parties.
The separation of LYMPHIR into Citius Oncology may not deliver the expected value creation or market benefits.
CTOR · Pharmaceutical Preparations
LIMN · Biological Products, (No Diagnostic Substances)
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
CHRS · Biological Products, (No Diagnostic Substances)
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
: 28/04/2026